Chardan Capital Reaffirms Buy Rating for Dyne Therapeutics (NASDAQ:DYN)
Dyne Therapeutics (NASDAQ:DYN – Get Free Report)‘s stock had its “buy” rating reiterated by investment analysts at Chardan Capital in a report issued on Monday,Benzinga reports. They currently have a $50.00 price objective on the stock. Chardan Capital’s price target points to a potential upside of 297.46% from the company’s previous close. Several other brokerages […]
Dyne Therapeutics (NASDAQ:DYN – Get Free Report)‘s stock had its “buy” rating reiterated by investment analysts at Chardan Capital in a report issued on Monday,Benzinga reports. They currently have a $50.00 price objective on the stock. Chardan Capital’s price target points to a potential upside of 297.46% from the company’s previous close. Several other brokerages […]
